TDOC posts narrower Q2 loss and trims costs, but shares dip as U.S. revenues and visit volumes decline.
Teladoc Health remains a deep value play at $7, trading at just 5-6x EBITDA, but lacks a clear growth catalyst. Revenue and user metrics are declining across core segments, with BetterHelp and Chronic Care both losing momentum and failing to innovate. Recent acquisitions (UpLift, Catapult Health) have not meaningfully expanded Teladoc's platform or addressed its reliance on basic telehealth connections.
Teladoc's Q2 2025 earnings reaffirm strong free cash flow guidance, with the potential to reach $220 million in the next twelve months. Despite an attractive 7x next year's free cash flow valuation, revenue growth remains stagnant and threatens the bull case. Profitability and an improving balance sheet keep me tepidly bullish, but lack of growth and competitive pressures are major risks.
Teladoc Health, Inc. Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Charles Divita - CEO & Director Mala Murthy - Chief Financial Officer Michael Minchak - Vice President of Investor Relations Conference Call Participants Sarah Elizabeth James - Cantor Fitzgerald & Co., Research Division Charles Rhyee - TD Cowen, Research Division Daniel R. Grosslight - Citigroup Inc., Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division Elizabeth Hammell Anderson - Evercore ISI Institutional Equities, Research Division Jailendra P.
The headline numbers for Teladoc (TDOC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Teladoc (TDOC) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.28 per share a year ago.
Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
I've upgraded Teladoc to a tepid buy—not a full conviction call, but the numbers finally tilt in its favor. I believe the company's innovative platform positions it as a leader in digital healthcare, driving long-term value. 7x forward free cash flow is just too low to ignore, even with weak top-line growth.
Teladoc (TDOC) concluded the recent trading session at $8.58, signifying a -1.49% move from its prior day's close.
Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
In the most recent trading session, Teladoc (TDOC) closed at $7.02, indicating a +2.33% shift from the previous trading day.
Teladoc Health, Inc. (NYSE:TDOC ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 11:30 AM ET Company Participants Charles Divita - CEO & Director Mala Murthy - Chief Financial Officer Conference Call Participants David Harrison Roman - Goldman Sachs Group, Inc., Research Division David Harrison Roman Very pleased to welcome the management team from Teladoc, Chuck Divita, Chief Executive Officer; and Mala Murthy, Chief Financial Officer. Very much appreciate you taking the time to participate in the conference and look forward to getting an update on Teladoc here.